MaxCyte (MXCT) Competitors

MaxCyte (NASDAQ:MXCT) and Ibotta (NYSE:IBTA) are both small-cap business services companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

Which has better valuation and earnings, MXCT or IBTA?

Ibotta has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Ibotta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MaxCyte	$38.63M	5.56	-$41.06M	-$0.40	-5.05
Ibotta	$367.25M	2.55	$68.74M	$1.48	24.95

Which has more volatility and risk, MXCT or IBTA?

MaxCyte has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, Ibotta has a beta of -1.29, suggesting that its stock price is 229% less volatile than the S&P 500.

Does the media prefer MXCT or IBTA?

In the previous week, MaxCyte had 1 more articles in the media than Ibotta. MarketBeat recorded 2 mentions for MaxCyte and 1 mentions for Ibotta. MaxCyte's average media sentiment score of 0.96 beat Ibotta's score of 0.00 indicating that MaxCyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MaxCyte	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ibotta	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do institutionals & insiders hold more shares of MXCT or IBTA?

68.8% of MaxCyte shares are owned by institutional investors. 3.3% of MaxCyte shares are owned by insiders. Comparatively, 16.1% of Ibotta shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Do analysts prefer MXCT or IBTA?

MaxCyte presently has a consensus price target of $7.50, suggesting a potential upside of 271.29%. Ibotta has a consensus price target of $61.60, suggesting a potential upside of 66.80%. Given MaxCyte's stronger consensus rating and higher probable upside, analysts plainly believe MaxCyte is more favorable than Ibotta.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MaxCyte	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Ibotta	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Is MXCT or IBTA more profitable?

Ibotta has a net margin of 16.24% compared to MaxCyte's net margin of -110.92%. Ibotta's return on equity of 15.04% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MaxCyte	-110.92%	-19.90%	-17.24%
Ibotta	16.24%	15.04%	9.71%

Summary

Ibotta beats MaxCyte on 9 of the 16 factors compared between the two stocks.